Company intelligence / Profile preview

TAAV Biomanufacturing Solutions

San Sebastián, Gipuzkoa, Spaintaav.com ↗

Ownership: Private
Development stage: Commercial

Overview

No direct clinical results; the company’s neDNA™/dbDNA™ platforms are used by partners to enable faster, safer AAV vector manufacturing for gene therapy applications. Their enzymatic DNA eliminates bacterial plasmid sequences and shortens timelines compared to traditional plasmid methods.

Therapeutic areas: Rare Diseases
Modalities: Synthetic DNA (neDNA™, dbDNA™)Adeno-associated virus vector (AAV) production support material
Industry: Non-Drug Biotech

Partnerships

Parent companies AskBio/Bayer AGBiopharma companies developing AAV-based gene therapies

Beyond the preview

Go deeper on TAAV Biomanufacturing Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAAV Biomanufacturing Solutions.

Explore the full profile